U.S. STOCKS ON THE MOVE-US banks, Biomea Fusion, Tutor Perini
U.S. STOCKS ON THE MOVE-Minerva Neurosciences, Midwest Holding, Global Payments
U.S. STOCKS ON THE MOVE-Norwegian Cruise Line, Marker Therapeutics, KBR
Erasca up as brain cancer therapy gets FDA's fast track tag
Brief: Erasca Granted FDA Fast Track Designation For CNS-Penetrant EGFR Inhibitor ERAS-801 In Patients With Glioblastoma
Brief: Erasca Announces Publication Of Promising Clinical Data Supporting The Therapeutic Potential Of Naporafenib In Combination With Trametinib In Nras-Mutant Melanoma
Brief: Erasca Presents Promising Initial Phase 1B Dose Escalation Data From Flagshp-1 For Eras-601 Plus Cetuximab In Patients With Advanced Solid Tumors At 2023 AACR Annual Meeting
Brief: Erasca's Shannon Morris Promoted To Chief Medical Officer
Erasca rises as Mizuho initates with 'buy' rating
U.S. RESEARCH ROUNDUP-Globus Medical, Philip Morris International, Vail Resorts
Brief: Erasca Reports Fourth Quarter Results
Brief: Erasca Announces First Patient Dosed In Herkules-1 Phase 1B Trial
Brief: Erasca Announces FDA Clearance Of IND Application For ERAS-3490
Brief: Erasca Enters Into License Agreement With Novartis Pharma
Brief: Erasca Announces Exclusive Worldwide License For Pan-RAF Inhibitor Naporafenib
Brief: Erasca Announces Pricing Of Underwritten Offering Of Common Stock
Brief: Erasca Announces Clinical Trial Collaboration And Supply Agreement With Pierre Fabre To Evaluate Eras-007 And Encorafenib Combination
Brief: Erasca Reports Third Quarter 2022 Financial Results
U.S. STOCKS ON THE MOVE-Lam Research, Cyngn, Par Pacific